The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.
 
Jay Oza
No Relationships to Disclose
 
Sahil Doshi
No Relationships to Disclose
 
Shing Mirn Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - AstraZeneca (Inst); Karyopharm Therapeutics (Inst); Merck (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Edwin Choy
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
 
Shahnaz V. Singh-Kandah
No Relationships to Disclose
 
Susana Hernandez
No Relationships to Disclose
 
Zoe Singer
No Relationships to Disclose
 
Swathi Balaji
No Relationships to Disclose
 
Lauren Franks
No Relationships to Disclose
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Daiichi Sankyo; Xencor
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; JOHNSON AND JOHNSON COM; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech